CN104744505B - A kind of vanadyl class complex and its application - Google Patents
A kind of vanadyl class complex and its application Download PDFInfo
- Publication number
- CN104744505B CN104744505B CN201510078860.1A CN201510078860A CN104744505B CN 104744505 B CN104744505 B CN 104744505B CN 201510078860 A CN201510078860 A CN 201510078860A CN 104744505 B CN104744505 B CN 104744505B
- Authority
- CN
- China
- Prior art keywords
- vanadyl
- class complex
- class
- complex
- application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 125000005287 vanadyl group Chemical group 0.000 title claims abstract description 54
- 239000003814 drug Substances 0.000 claims abstract description 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 11
- 150000001875 compounds Chemical class 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 10
- 201000010099 disease Diseases 0.000 claims description 8
- 108090000623 proteins and genes Proteins 0.000 claims description 8
- 201000006474 Brain Ischemia Diseases 0.000 claims description 6
- 206010008120 Cerebral ischaemia Diseases 0.000 claims description 6
- 206010008118 cerebral infarction Diseases 0.000 claims description 6
- 208000024827 Alzheimer disease Diseases 0.000 claims description 5
- 210000004556 brain Anatomy 0.000 claims description 5
- 102000004169 proteins and genes Human genes 0.000 claims description 5
- 208000030886 Traumatic Brain injury Diseases 0.000 claims description 4
- 230000003961 neuronal insult Effects 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 230000009529 traumatic brain injury Effects 0.000 claims description 4
- 210000000349 chromosome Anatomy 0.000 claims description 3
- 210000000653 nervous system Anatomy 0.000 claims description 3
- XUHRVZXFBWDCFB-QRTDKPMLSA-N (3R)-4-[[(3S,6S,9S,12R,15S,18R,21R,24R,27R,28R)-12-(3-amino-3-oxopropyl)-6-[(2S)-butan-2-yl]-3-(2-carboxyethyl)-18-(hydroxymethyl)-28-methyl-9,15,21,24-tetrakis(2-methylpropyl)-2,5,8,11,14,17,20,23,26-nonaoxo-1-oxa-4,7,10,13,16,19,22,25-octazacyclooctacos-27-yl]amino]-3-[[(2R)-2-[[(3S)-3-hydroxydecanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoic acid Chemical compound CCCCCCC[C@H](O)CC(=O)N[C@H](CC(C)C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H]1[C@@H](C)OC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CO)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC1=O)[C@@H](C)CC XUHRVZXFBWDCFB-QRTDKPMLSA-N 0.000 claims 2
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 claims 2
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 claims 2
- 102000008068 Tensins Human genes 0.000 claims 2
- 108010088950 Tensins Proteins 0.000 claims 2
- 230000007812 deficiency Effects 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 2
- 230000000740 bleeding effect Effects 0.000 claims 1
- 125000004430 oxygen atom Chemical group O* 0.000 claims 1
- 229940123940 PTEN inhibitor Drugs 0.000 abstract description 4
- 229940079593 drug Drugs 0.000 abstract description 3
- 230000009471 action Effects 0.000 abstract description 2
- 231100000053 low toxicity Toxicity 0.000 abstract description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 18
- 210000004027 cell Anatomy 0.000 description 16
- 230000000694 effects Effects 0.000 description 14
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 14
- 108010011536 PTEN Phosphohydrolase Proteins 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 102000014160 PTEN Phosphohydrolase Human genes 0.000 description 11
- 108091008611 Protein Kinase B Proteins 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 150000001408 amides Chemical class 0.000 description 8
- 150000002978 peroxides Chemical group 0.000 description 8
- 235000019253 formic acid Nutrition 0.000 description 7
- 150000002460 imidazoles Chemical class 0.000 description 7
- -1 oxo vanadic acid Chemical compound 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 230000003213 activating effect Effects 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- GNTDGMZSJNCJKK-UHFFFAOYSA-N divanadium pentaoxide Chemical compound O=[V](=O)O[V](=O)=O GNTDGMZSJNCJKK-UHFFFAOYSA-N 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 241000700159 Rattus Species 0.000 description 5
- 238000000540 analysis of variance Methods 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 4
- 206010008089 Cerebral artery occlusion Diseases 0.000 description 4
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 230000010261 cell growth Effects 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 238000007872 degassing Methods 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 238000001819 mass spectrum Methods 0.000 description 4
- 201000007309 middle cerebral artery infarction Diseases 0.000 description 4
- 210000005036 nerve Anatomy 0.000 description 4
- 208000015122 neurodegenerative disease Diseases 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000010189 synthetic method Methods 0.000 description 4
- PKDBCJSWQUOKDO-UHFFFAOYSA-M 2,3,5-triphenyltetrazolium chloride Chemical compound [Cl-].C1=CC=CC=C1C(N=[N+]1C=2C=CC=CC=2)=NN1C1=CC=CC=C1 PKDBCJSWQUOKDO-UHFFFAOYSA-M 0.000 description 3
- 101710088194 Dehydrogenase Proteins 0.000 description 3
- 208000032612 Glial tumor Diseases 0.000 description 3
- 206010018338 Glioma Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 208000001738 Nervous System Trauma Diseases 0.000 description 3
- 206010029260 Neuroblastoma Diseases 0.000 description 3
- 208000018737 Parkinson disease Diseases 0.000 description 3
- 102000002727 Protein Tyrosine Phosphatase Human genes 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000000302 ischemic effect Effects 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 208000028412 nervous system injury Diseases 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 108020000494 protein-tyrosine phosphatase Proteins 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 102000013563 Acid Phosphatase Human genes 0.000 description 2
- 108010051457 Acid Phosphatase Proteins 0.000 description 2
- 206010008190 Cerebrovascular accident Diseases 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 102100033810 RAC-alpha serine/threonine-protein kinase Human genes 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 238000001994 activation Methods 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 229910052786 argon Inorganic materials 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000030609 dephosphorylation Effects 0.000 description 2
- 238000006209 dephosphorylation reaction Methods 0.000 description 2
- 239000012065 filter cake Substances 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- FIKAKWIAUPDISJ-UHFFFAOYSA-L paraquat dichloride Chemical compound [Cl-].[Cl-].C1=C[N+](C)=CC=C1C1=CC=[N+](C)C=C1 FIKAKWIAUPDISJ-UHFFFAOYSA-L 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 235000019624 protein content Nutrition 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- 0 *c1c[n]cn1 Chemical compound *c1c[n]cn1 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- ROFVEXUMMXZLPA-UHFFFAOYSA-N Bipyridyl Chemical compound N1=CC=CC=C1C1=CC=CC=N1 ROFVEXUMMXZLPA-UHFFFAOYSA-N 0.000 description 1
- NCXSSEGRSONVQV-UHFFFAOYSA-N CC(C(C1=O)=O)=C1Nc1ccccn1 Chemical compound CC(C(C1=O)=O)=C1Nc1ccccn1 NCXSSEGRSONVQV-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 1
- 229940124036 Hydrolase inhibitor Drugs 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 101150073900 PTEN gene Proteins 0.000 description 1
- YNPNZTXNASCQKK-UHFFFAOYSA-N Phenanthrene Natural products C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 description 1
- 101710177166 Phosphoprotein Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 159000000013 aluminium salts Chemical class 0.000 description 1
- 229910000329 aluminium sulfate Inorganic materials 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 230000002414 glycolytic effect Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000004093 hydrolase inhibitor Substances 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 208000037906 ischaemic injury Diseases 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 210000003140 lateral ventricle Anatomy 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 150000003905 phosphatidylinositols Chemical class 0.000 description 1
- 229940067626 phosphatidylinositols Drugs 0.000 description 1
- 150000003906 phosphoinositides Chemical class 0.000 description 1
- 108091005981 phosphorylated proteins Proteins 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000010410 reperfusion Effects 0.000 description 1
- 230000000250 revascularization Effects 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 210000001032 spinal nerve Anatomy 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- IBYSTTGVDIFUAY-UHFFFAOYSA-N vanadium monoxide Chemical compound [V]=O IBYSTTGVDIFUAY-UHFFFAOYSA-N 0.000 description 1
- UUUGYDOQQLOJQA-UHFFFAOYSA-L vanadyl sulfate Chemical compound [V+2]=O.[O-]S([O-])(=O)=O UUUGYDOQQLOJQA-UHFFFAOYSA-L 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
Abstract
Description
Claims (8)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510078860.1A CN104744505B (en) | 2015-02-13 | 2015-02-13 | A kind of vanadyl class complex and its application |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510078860.1A CN104744505B (en) | 2015-02-13 | 2015-02-13 | A kind of vanadyl class complex and its application |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104744505A CN104744505A (en) | 2015-07-01 |
CN104744505B true CN104744505B (en) | 2017-07-11 |
Family
ID=53584832
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510078860.1A Active CN104744505B (en) | 2015-02-13 | 2015-02-13 | A kind of vanadyl class complex and its application |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104744505B (en) |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3270695B2 (en) * | 1996-12-02 | 2002-04-02 | 山本化成株式会社 | Method for producing vanadyl naphthalocyanine compound |
CA2563316A1 (en) * | 2004-04-06 | 2005-10-20 | Semafore Pharmaceuticals, Inc. | Pten inhibitors |
US9259438B2 (en) * | 2008-01-17 | 2016-02-16 | Kui Liu | Methods for in vitro maturation of ovarian follicles |
-
2015
- 2015-02-13 CN CN201510078860.1A patent/CN104744505B/en active Active
Also Published As
Publication number | Publication date |
---|---|
CN104744505A (en) | 2015-07-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7085073B2 (en) | Topical compositions and methods for treating inflammatory skin diseases | |
CN106139144B (en) | A kind of hyaluronic acid decorated gold-Nano carbon balls and the preparation method and application thereof with synergistic antitumor characteristic | |
CN105111271B (en) | A kind of ursolic acid-Aspirin Conjugate and the application in preparation prevention tumor metastasis medicine thereof | |
JPWO2005060935A1 (en) | Nanoparticles containing drug, method for producing the same, and preparation for parenteral administration comprising the nanoparticles | |
CN101524331B (en) | Polysaccharide-liposome and preparation method and purpose thereof | |
CN108350009A (en) | The big cyclic rings complex compound of pentaaza with oral bioavailability rate | |
WO2015172712A1 (en) | Pharmaceutical composition for injection with synergistic effect of vitamin c and antitumour drugs | |
MX2011001410A (en) | Lower dosage strength imiquimod formulations and short dosing regimens for treating genital and perianal warts. | |
CN102657602B (en) | 3,5-dyhydroxyl-4-isopropyl diphenylethene chitosan gel and preparation method thereof | |
JP6463745B2 (en) | Icotinib-containing external pharmaceutical composition and its application | |
CN104744505B (en) | A kind of vanadyl class complex and its application | |
CN106913882A (en) | A kind of polyethylene glycol gambogicacid liposome and preparation method and its application in malignant tumour is treated | |
CN103505414B (en) | Butylphthalide nasal drop and preparation method thereof | |
CN113599537B (en) | Nano aggregate and preparation method and application thereof | |
KR20200112012A (en) | Compositions for skin wound healing and regeneration comprising (R)-Ginsenoside Rg3 | |
JP6547228B2 (en) | NANOPARTICLE AND NANOPARTICLE COMPOSITION AND METHOD FOR PRODUCING THE SAME | |
CN108703977B (en) | Application of cyanobacteria and membrane-outer vesicle thereof in preparation of medicine for treating diseases | |
CN101844994A (en) | Gossypol amino-acid derivative for blocking invasion of human immunodeficiency viruses and preparation method and application thereof | |
JP2007326796A (en) | Bleaching agent containing gold colloid and thyrosinase inhibitor | |
JPH10147534A (en) | Tumor newborn blood vessel inhibitor and medicine composition | |
CN105663060B (en) | A kind of dianhydrogalactitol lipidosome freeze-dried injection and preparation method thereof | |
JP6656890B2 (en) | Filaggrin production promoter | |
CN101161652B (en) | Quinolizine derivatives having antibacterial activity | |
JP7361448B2 (en) | Transglutaminase expression promoter | |
JPWO2004069261A1 (en) | Method for producing anti-herpesvirus external preparation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB03 | Change of inventor or designer information | ||
CB03 | Change of inventor or designer information |
Inventor after: Wan Sha Inventor after: Zhou Haibing Inventor after: Han Xin Inventor after: Zhang Zhifeng Inventor after: Chen Juan Inventor after: Wang Wei Inventor before: Wan Chi Inventor before: Wan Sha Inventor before: Zhou Haibing Inventor before: Han Xin Inventor before: Zhang Zhifeng Inventor before: Chen Juan Inventor before: Wang Wei |
|
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20170613 Address after: 430014 B1 building, BCD District, Wuhan national biological industry base project, Hubei, China Applicant after: WUHAN HONGYUE MEDICAL SCIENCE Inc. Address before: 430074 Hubei city of Wuhan Province Lu Mill Road South villa 7-3-1101 Applicant before: Wan Chi Applicant before: Wan Sha |
|
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20240820 Address after: 430072 No. 299 Bayi Road, Wuchang District, Hubei, Wuhan Patentee after: WUHAN University Country or region after: China Address before: Building B1, Research and Development Building, BCD District, Wuhan National Biotechnology Industry Base Project, Hubei Province 430014 Patentee before: WUHAN HONGYUE MEDICAL SCIENCE Inc. Country or region before: China |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20240911 Address after: 430000 R&D Building B1 of Wuhan National Biological Industrial Base Project B, C and D, 666 High-tech Avenue, Donghu High-tech Development Zone, Wuhan City, Hubei Province Patentee after: WUHAN HONGYUE MEDICAL SCIENCE Inc. Country or region after: China Patentee after: WUHAN University Address before: 430072 No. 299 Bayi Road, Wuchang District, Hubei, Wuhan Patentee before: WUHAN University Country or region before: China |